Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of a single administration
of RT001 compared to placebo gel for the treatment of moderate to severe lateral canthal
lines.
Phase:
Phase 2
Details
Lead Sponsor:
Revance Therapeutics, Inc.
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA